[A double blind study of the new hypolipidemic agent pirozadil (722-D) using patients with ischemic heart disease (author's transl)].
D000368:Aged; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D011897:Random Allocation
D000960:Hypolipidemic Agents; D011725:Pyridines; C005681:alfibrate; D002995:Clofibric Acid; C015453:pirozadil
Estudio doble ciego con un nuevo producto hipolipidemiante, el pirozadil (722-D), desde el punto de vista comparativo con alufibrato en enfermos afectos de cardiopatía isquémica.